RxDoctor Payments Data

Alexandru Marginean, MD

Cardiovascular Disease · Valparaiso, INNPI 1669829354

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 18 payments — averaging $55.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$535
  • Abbott$210
  • Pfizer$140
  • Novartis$40
  • Merck$29
  • Johnson & Johnson$26
  • plus $21 from 2 others

What the payments were for

  • Travel & lodging$20520%
  • Food & beverage$79680%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$189,286
Medicare patients
1,905
Services billed
3,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban338$354,214
EntrestoSacubitril/Valsartan66$92,332
XareltoRivaroxaban58$68,724
Repatha SureclickEvolocumab55$54,764
BrilintaTicagrelor20$23,818
Metoprolol Succinate501$4,947
Ranolazine ErRanolazine20$4,858
Ezetimibe211$4,780
Atorvastatin Calcium588$4,302
Diltiazem 12hr ErDiltiazem Hcl22$3,647
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,305
Rosuvastatin Calcium238$2,792
Amiodarone Hcl53$2,251
ClopidogrelClopidogrel Bisulfate310$2,140
Prasugrel Hcl13$1,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$354,214338 claims
NovartisEntresto$40$92,33266 claims
Johnson & JohnsonXarelto$26$68,72458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →